Overview of Ко-Перинева

Quick Facts

Property	Description
Active Ingredients	Perindopril and Indapamid
Form	Film-coated tablets
Pharmacological Class	ACE Inhibitor and Thiazide-like Diuretic combination
Common Use	Management of Essential Hypertension
Origin	Synthetic

Definition and Pharmacological Classification

Ко-Перинева is defined as a synthetic, prescription-only medication classified as a potent antihypertensive drug intended for the long-term management of high blood pressure. It is presented as a fixed-dose combination (FDC) tablet for oral administration, integrating two distinct therapeutic agents into one preparation. The strategy of combining an ACE inhibitor and a diuretic in a single pill is clinically recognized for achieving effective blood pressure control. This combined approach is established for its ability to provide better and more sustained control over high blood pressure than single-drug therapy.

Composition and General Purpose

The medication's core identity is rooted in its two distinct active ingredients: Perindopril and Indapamid. Perindopril is an Angiotensin-Converting Enzyme (ACE) inhibitor that promotes vasodilation (widening of blood vessels), thereby reducing vascular resistance. Indapamid is a thiazide-like diuretic that controls fluid volume by encouraging the excretion of salt and water. This combination, known by several trade names globally including Preterax and Noliprel, represents a standard, established strategy in cardiovascular pharmacology. Pharmacological data indicate that the FDC of Perindopril/Indapamide is associated with consistent reductions in both systolic and diastolic blood pressure, leading to effective cardiovascular risk management. The primary general purpose of Ко-Перинева is to provide this stable, comprehensive control over essential hypertension in adults requiring dual therapy.

Regulatory References

MedlinePlus Drug Information on Perindopril

What side effects are possible with Ко-Перинева?

Possible Side Effects and Safety Information

Regulatory documentation for the Perindopril/Indapamid combination (Ко-Перинева) details the official safety profile by classifying adverse reactions based on frequency and system-organ involvement, strictly defining the medicine's risk characteristics.

Frequency-Classified Adverse Reactions

The adverse reactions documented in official prescribing information are grouped by their expected rate of occurrence:

Common (ge 1/100 to <1/10): Reactions frequently reported include headache, dizziness, cough (often dry and persistent), vertigo, gastrointestinal discomfort (such as nausea, constipation, or diarrhea), and general asthenia (weakness).
Uncommon (ge 1/1,000 to <1/100): Documented effects at this frequency include hypotension (low blood pressure), sleep disturbances, syncope, photosensitivity reactions, and Angioedema (swelling of the face, limbs, or airway).
Very Rare (<1/10,000): Rare but severe adverse effects listed are Agranulocytosis, Pancreatitis, Hepatic encephalopathy (in those with pre-existing liver issues), and severe skin disorders such as Toxic Epidermal Necrolysis.

Serious Adverse Reactions and Safety Constraints

The label documents specific serious adverse reactions and high-level constraints. Angioedema is a critical, documented risk that may occur at any time during treatment. Safety regulations define specific patient groups for whom the medicine is contraindicated, including patients who are in the second and third trimesters of pregnancy, those with severe hepatic impairment, or those with pre-existing hypokalaemia (low potassium). Regulatory notes also highlight that Hypotension is most likely to occur in patients with pre-existing volume or salt depletion.

Overdose and Emergency Response

The official regulatory profile for a suspected overdose of Ко-Перинева focuses on severe physiological disturbances resulting from excessive vasodilation and volume depletion.

Documented Overdose Manifestations and Outcomes

The most frequent clinical signs documented in regulatory sources are profound hypotension (excessively low blood pressure) and acute electrolyte disturbances, including hypokalaemia (low potassium) and hyponatremia (low sodium). These can lead to non-specific symptoms such as severe dizziness, confusion, muscular weakness, and excessive diuresis (urine output). The overdose profile also includes the risk of laryngeal angioedema—swelling of the throat—which may cause airway obstruction and is classified as a potentially fatal outcome associated with the Perindopril component.

Required Emergency Actions and Management

Immediate medical attention is required for any suspected overdose. Emergency services (e.g., 911) must be contacted immediately for life-threatening symptoms such as trouble breathing or passing out. In all cases, a poison control center should be contacted for guidance. Management is strictly symptomatic and supportive, as no specific antidote is known. Hospital monitoring and continuous close medical supervision are mandated, with frequent checks of electrolytes and renal function being required. Interventions may include intravenous fluid administration (saline) and, for severe cases, consideration of dialysis for the removal of the active metabolite, Perindoprilat. Official documents note an increased risk of severe electrolyte imbalance in elderly patients.

Therapeutic Uses of Ко-Перинева

What Ko-Perineva Treats: Main Uses and Benefits

Ko-Perineva is a dual-component medication primarily used for managing essential hypertension (high blood pressure). This combination is indicated for the treatment of this condition and is relevant in therapeutic domains to provide supportive relief and assist patients with maintaining stability.

The medicine is commonly used across conditions characterized by periods of heightened symptoms or episodic manifestations, and it is applied in clinical settings where short-term symptomatic assistance is needed. It helps address groups of symptoms that can become intense or disruptive, particularly those related to heightened physiological activity that creates noticeable strain. It generally contributes to easing the overall symptom load and supports the patient during difficult episodes.

“This medication is considered relevant in contexts marked by increased discomfort or tension related to the condition, where supportive management is appropriate.”

Quick Fact: Support for Heightened Symptoms

Ko-Perineva is used for conditions presenting with disruptive symptom manifestations and offers symptomatic relief that assists with maintaining functional stability when symptoms interfere with routine activities.

Regulatory References

Health Canada's Drug and Health Product Register

Eligibility and Restrictions for Use

Who Can and Cannot Use Ко-Перинева?

This section summarizes the official population eligibility and non-eligibility rules for Ко-Перинева (Perindopril/Indapamide), based strictly on governmental regulatory documents.

Contraindications and Non-Eligibility

Category	Regulatory Status
Hypersensitivity	Contraindicated in patients with known allergy to any component, another ACE inhibitor, or any sulfonamide-derived drug.
Angioedema History	Contraindicated in patients with a history of angioedema (swelling) related to previous ACE inhibitor therapy or any hereditary/idiopathic angioedema.
Pregnancy	Contraindicated during the second and third trimesters. Use is not recommended during the first trimester.
Organ Function	Contraindicated in severe renal impairment ( CrCl < 30 mL/min) and severe hepatic impairment or hepatic encephalopathy.
Pediatric Use	Not recommended for children and adolescents under 18 years; safety and efficacy have not been established.
Renal Artery	Contraindicated in bilateral renal artery stenosis or stenosis to a single functioning kidney.

Eligibility and Conditional Use

Ко-Перинева is approved for use in adults who do not meet any of the above contraindication criteria. Use in older adults is generally permitted, but requires frequent monitoring of renal function and potassium levels. Patients with moderate renal or hepatic impairment may be eligible, but this requires caution and often dose adjustment due to regulatory restrictions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes medically significant interactions for the combination product Ко-Перинева (Perindopril/Indapamide) as documented in official regulatory labeling.

Contraindicated Combinations and Restrictions

Certain combinations are prohibited due to high risk of adverse events:

Sacubitril/Valsartan (ARNI): Co-administration is contraindicated due to the risk of angioedema. A 36-hour washout period is mandatory between the last dose of Perindopril and the initiation of Sacubitril/Valsartan.
Aliskiren: Use is contraindicated in patients with diabetes mellitus or those with moderate-to-severe renal impairment.
Extracorporeal Treatments: Procedures where blood is exposed to negatively charged surfaces (e.g., specific dialysis types) are restricted due to severe anaphylactoid reaction risk.

Clinically Significant Pharmacodynamic Interactions

Interactions that alter the medication's effects or body chemistry include:

Potassium-Sparing Diuretics/Potassium Supplements: Co-administration is typically not recommended as it significantly increases the risk of hyperkalemia (high potassium levels).
Lithium: Concomitant use with this combination may lead to a dangerous increase in serum lithium levels and symptoms of toxicity.
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): These agents may diminish the blood pressure-lowering effect and increase the risk of acute renal function deterioration.

No significant pharmacokinetic change between Perindopril and Indapamide is documented when co-administered.

Mechanism of Action

Ко-Перинева is a combination product whose pharmacodynamic effect is derived from the distinct molecular mechanisms of its two components: Perindopril and Indapamide.

Perindopril is a pro-drug that is metabolized into Perindoprilat, an active, competitive inhibitor of Angiotensin-Converting Enzyme (ACE). ACE inhibition blocks the conversion of Angiotensin I to the potent vasoconstrictor, Angiotensin II, thereby decreasing circulating and tissue levels of Angiotensin II. This also prevents the enzymatic degradation of Bradykinin, a vasodilatory peptide, leading to its accumulation. The consequence is reduced systemic vascular resistance.

Indapamide functions by inhibiting sodium reabsorption primarily in the cortical segment of the distal convoluted tubule of the nephron. This action increases the excretion of sodium and chloride ions, resulting in enhanced water output. Additionally, Indapamide is observed to modulate vascular reactivity by altering the transmembrane transport of ions like calcium in vascular smooth muscle cells, contributing to localized vasodilation.

Dosage and Administration Information

Ко-Перинева is a fixed-dose combination therapy administered exclusively via the oral route as a film-coated tablet for the long-term management of essential hypertension. The regimen is typically for the medication to be taken once daily. Administration must be done in the morning and before a meal, such as breakfast, to ensure optimal absorption of the active components. The tablet must be swallowed whole with water and should not be crushed or chewed.

Therapy typically starts with the lowest available strength, such as 2 mg/0.625 mg (Perindopril/Indapamide). The dose may be adjusted sequentially by the treating clinician, based on the patient's response, up to the maximum labeled strength of 8 mg/2.5 mg once daily. If a patient misses a dose, it is recommended to skip the forgotten dose and resume the regular schedule on the next day, rather than taking a double dose at once.

Specific protocols apply for certain populations. For older adults, the lowest dose should be used for treatment initiation. Furthermore, in patients with moderate renal impairment (Creatinine Clearance 30–60 mL/min), the maximum dose is strictly limited to 2 mg/0.625 mg daily. Use of the FDC is not recommended for pediatric patients under 18 years of age.

Recent Clinical Evidence

Co-Perineva: Recent Clinical Evidence

The combination compound Co-Perineva (Perindopril and Indapamide) is assessed primarily for its effectiveness in managing hypertension (high blood pressure) and preventing associated cardiovascular events.

Management of Hypertension

Clinical studies have consistently demonstrated that fixed-dose combinations, such as Co-Perineva, provide a synergistic effect in lowering blood pressure. The dual mechanism, combining an ACE inhibitor (Perindopril) with a diuretic (Indapamide), targets both the renin-angiotensin system and volume control, leading to greater blood pressure reduction compared to either agent used alone at similar doses. This fixed-dose approach is often recommended to improve treatment adherence.

Reduction of Cardiovascular Risk

Research evidence supports the role of this combination in cardioprotection beyond simple blood pressure reduction. Key findings from large-scale trials have shown:

Stroke Prevention: The Perindopril-Indapamide combination has been associated with a significant reduction in the risk of stroke, particularly in patients with a history of hypertension or prior stroke.
Major Cardiovascular Events (MACE): Studies evaluating high-risk populations, including those with stable coronary artery disease, reported that this combination regimen may lower the incidence of major cardiovascular events, such as myocardial infarction (heart attack) and heart failure hospitalization.

Tolerability and Safety

The fixed-dose combination generally maintains a favorable safety and tolerability profile. The most frequently reported adverse events are common to ACE inhibitors (e.g., cough) and diuretics (e.g., hypokalemia). However, the specific doses used in the combination may help mitigate certain side effects while providing maximal benefit.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Ко-Перинева (FAQ)

Q: How quickly does Ко-Перинева usually start working?

Initial effects such as dizziness or low blood pressure may be noticed after the very first dose or whenever the dose is adjusted. However, official product information indicates that the maximum, stable blood pressure reduction is generally expected to occur after a few weeks of consistent treatment.

Q: How long does the effect of one dose of Ко-Перинева last?

Regulatory documents indicate the medicine is intended to be dosed once daily, which aligns with an expected duration of effect covering a 24-hour period.

Q: Can Ко-Перинева be taken long-term?

Yes. According to regulatory documents, this product is indicated for the long-term management of essential hypertension (high blood pressure). It is often used as substitution therapy for patients who are already well-controlled on its individual components.

Q: Is it better to take Ко-Перинева in the morning or at night?

Regulatory documents specify that the single daily dose should preferably be taken in the morning. Regulatory documents specify that the tablet should be taken before a meal, such as breakfast.

Q: Can Ко-Перинева affect the ability to drive or operate machinery?

Side effects like dizziness or weakness due to low blood pressure may occur in some patients. Official patient information highlights the need for caution when driving or operating machinery until an individual observes how the medicine affects them.

Q: Is Ко-Перинева safe to use during pregnancy?

The medicine is contraindicated (prohibited) during the second and third trimesters of pregnancy. Its use is also officially not recommended during the first trimester. If pregnancy is diagnosed while taking the medicine, treatment should be stopped immediately.

Q: Why is it a combination pill and not two separate ones?

Clinical studies support the use of fixed-dose combinations because they achieve a synergistic effect, meaning they work together for a greater overall blood pressure reduction. Official information also notes that the use of a single combination pill is often a strategy used to improve patient adherence to the treatment plan.

Q: What is the difference between taking Ко-Перинева and taking Perindopril alone?

Ко-Перинева contains two active components: an ACE inhibitor (Perindopril) and a diuretic (Indapamide). Clinical evidence indicates that this dual mechanism leads to greater blood pressure reduction and more comprehensive control compared to using Perindopril alone at similar doses.

Q: Are there any serious side effects associated with Ко-Перинева that people worry about?

Official documentation lists certain adverse reactions that are classified as very rare, including severe issues like Agranulocytosis, Pancreatitis, and severe skin disorders. Angioedema (swelling of the face, limbs, or airway) is also a documented, serious risk associated with this class of medication.

Q: Can I take Ко-Перинева if I have diabetes?

Regulatory documents indicate that caution is advised for patients with diabetes. It is also specifically noted that the medicine's use with the blood pressure drug Aliskiren is contraindicated (prohibited) in patients with diabetes.

Q: Are there reasons why a person with liver issues might not be able to use Ко-Перинева?

Yes, this medicine is contraindicated (prohibited) in patients with severe hepatic impairment (severe liver issues) or a condition called hepatic encephalopathy. The Indapamide component may cause or worsen hepatic encephalopathy when liver function is already severely impaired.

Q: What is the guidance on using Ко-Перинева while breastfeeding?

According to official regulatory documents, the use of this medicine is contraindicated (prohibited) during lactation, or breastfeeding. The Perindopril component is also not recommended for use while breastfeeding.

Q: Does Ко-Перинева interact with common pain relievers like ibuprofen?

Official information states that the combination is known to interact with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which include common relievers like ibuprofen. This combination may reduce the blood pressure-lowering effect and potentially increase the risk of deterioration in kidney function.

Q: Can Ко-Перинева cause changes in my blood test results?

The medicine can affect certain laboratory values, particularly serum potassium levels (it may cause hypokalemia or hyperkalemia). It may also interfere with certain other lab tests, such as those checking liver or kidney function. The monitoring of these levels is a recognized component of clinical follow-up.

Q: Is it necessary to have blood tests done while taking Ко-Перинева?

Official medical follow-up for patients taking this medicine typically includes frequent monitoring of creatinine (to check kidney function) and potassium levels. This monitoring is particularly emphasized for older adults and those with existing kidney impairment.

Q: Why do doctors prescribe this specific combination instead of other blood pressure medicines?

Clinical evidence supports the use of this specific combination because its dual mechanisms achieve superior blood pressure reduction. Furthermore, this regimen has been associated with a documented reduction in the risk of stroke and major cardiovascular events in high-risk patient populations examined in clinical studies.

Q: Does Ко-Перинева treat the cause of high blood pressure or just the symptoms?

The medication is a management tool that acts on key mechanisms contributing to high blood pressure. It works by blocking certain hormones and promoting the excretion of salt and water. This effectively addresses and manages the pressure itself, which is considered the symptom in essential hypertension.

Q: If I am taking lithium, are there known issues with Ко-Перинева?

Official regulatory information states that the use of this medicine with lithium may lead to a dangerous increase in serum lithium levels. This interaction can potentially result in symptoms of lithium toxicity.

Q: Is there a maximum time frame for how long a person should use Ко-Перинева?

The product is indicated for the long-term management of essential hypertension, and regulatory documents do not specify a maximum time limit for its use. Continued treatment involves ongoing monitoring of certain laboratory parameters, as outlined in prescribing documents.

Q: Does the medicine need to be taken with food?

Official administration instructions specify that the tablet should be taken before a meal, such as breakfast. The administration instructions specify that the dose should be taken before a meal.

Q: Are there studies comparing Ко-Перинева to taking the two medicines separately?

Yes. Clinical studies have shown that the fixed-dose combination provides greater overall blood pressure reduction compared to using the individual agents alone at similar doses. The fixed-dose combination approach is also often utilized as a strategy to help patients with adherence to their treatment.

Q: Is Ко-Перинева appropriate for older adults (seniors)?

Use in older adults is permitted according to regulatory guidelines, but treatment should be initiated at the lowest available dose. Regulatory documents indicate that this population should have frequent monitoring of renal function and potassium levels.

Q: What are the general expectations for blood pressure reduction when using Ко-Перинева?

Clinical evidence confirms that this combination is associated with consistent and effective reductions in both systolic and diastolic blood pressure. The dual action is documented to provide effective and more sustained control over high blood pressure compared to single-drug therapy.

How should Ко-Перинева be stored and disposed of?

How to Store and Dispose of Ko-Perineva (Perindopril/Indapamide)

Official regulatory labeling dictates specific conditions for the storage and disposal of Ko-Perineva to maintain product stability and ensure environmental protection.

Storage Requirements

The medicine must be stored at a temperature that does not exceed 30°C. It must be kept in the original package to ensure protection from moisture and light, and it is a mandatory safety requirement to keep this medicine out of the sight and reach of children.

Stability and Disposal

The product must not be used after the expiry date printed on the packaging. For certain product configurations, any remaining tablets must be discarded two months after opening the pouch.

When disposing of the medicine, do not throw the tablets away via wastewater or household waste. All unused or expired medicinal products must be disposed of in accordance with local pharmaceutical requirements by consulting a pharmacist.

Ко-Перинева